II. Precautions: Pharmacogenetics

  1. See Pharmacogenetics
  2. Poor metabolizers (2-15%, 20% in asians)
    1. Clopidogrel with reduced conversion to active form (higher risk for stent closure)
    2. Amitriptyline and Nortriptyline risk of toxicity (reduce starting dose by 50%)
    3. Citalopram, Escitalopram, Sertraline risk of toxicity (reduce starting dose by 50%)
    4. Omeprazole blood concentrations are 5x higher (increased efficacy)
  3. Ultra-Metabolizers (18% of Swedes and 18% of Ethiopians)
    1. Citalopram, Escitalopram, Sertraline with reduced effect (consider alternative agents)
    2. Omeprazole blood concentrations are 40% lower
  4. Reference
    1. Sim (2006) Clin Pharmacol Ther 79:103-13 [PubMed]

III. Interactions: Metabolized by CYP2C19 (Substrates)

IV. Interactions: Inhibitor of CYP2C19

  1. Neuropsychiatric drugs
    1. Fluvoxamine (Luvox)
  2. Antibiotics
    1. Isoniazid (INH)
    2. Ritonavir
  3. Miscellaneous
    1. Omeprazole (Prilosec)
    2. Cimetidine

V. Interactions: Inducer of CYP2C19

Images: Related links to external sites (from Bing)

Related Studies